xtandi
astellas pharma europe b.v. - enzalutamide - prostatic neoplasms - endocrine therapy - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5.1).the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
zavesca 100mg capsules
actelion pharmaceuticals uk ltd - miglustat - capsule - 100mg
dificlir 200mg tablets
astellas pharma ltd - fidaxomicin - tablet - 200mg
uptravi 200microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 200microgram
uptravi 400microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 400microgram
uptravi 600microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 600microgram
uptravi 800microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 800microgram
uptravi 1,000microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 1mg
uptravi 1,200microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 1.2mg
uptravi 1,400microgram tablets
actelion pharmaceuticals uk ltd - selexipag - tablet - 1.4mg